XBIO Xenetic Biosciences, Inc. - Common Stock
$3.25
价格 · 八月 18, 2026
截至...的财报数据 八月 6, 2026
关于 Xenetic Biosciences, Inc. - Common Stock 公司概况（来自维基百科）
XBIO 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$3.25
市值
—
P/E (TTM)
-1.4
每股收益 (TTM)
$-1.58
营收 (TTM)
$3M
股息收益率
—
ROE
—
负债/权益
—
52周区间
$2 – $14
XBIO 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$3M
2016-12-31
→
2025-12-31
EPS
$-1.58
2021-12-31
→
2025-12-31
自由现金流
—
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
XBIO
同行中位数
P/E (TTM)
-1.4
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
XBIO
同行中位数
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
XBIO
同行中位数
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
XBIO
同行中位数
Revenue YoY (营收同比增长)
19.0%
—
Revenue CAGR 3Y (营收3年复合年增长率)
20.4%
—
Revenue CAGR 5Y (营收5年复合年增长率)
46.8%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
XBIO
同行中位数
XBIO 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
卖出
6 位分析师
- 强烈买入 0 0.0%
- 买入 0 0.0%
- 持有 3 50.0%
- 卖出 1 16.7%
- 强烈卖出 2 33.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.07%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2025年6月30日 | $-0.45 | $-0.65 | 0.20% |
| 2025年3月31日 | $-0.59 | $-0.73 | 0.14% |
| 2024年12月31日 | $-0.68 | $-0.20 | -0.48% |
| 2024年9月30日 | $-0.28 | $-0.14 | -0.14% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| XBIO | — | -1.4 | 19.0% | — | — | — |
| AQB | $4M | -0.2 | -21.2% | — | -315.5% | — |
| BOLT | $11M | -0.3 | 0.07% | -433.7% | -102.2% | — |
| CDIO | — | — | — | — | — | — |
| DRMA | — | — | — | — | — | — |
| PMCB | $8M | -0.3 | — | — | -56.7% | — |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| BCAB | — | -0.6 | — | — | — | — |
| LABT | — | — | — | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $3M | $3M | $2M | $1M | $436.9K | $17.1K | $0 | $8M | $3M | $0 | $0 | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| R&D Expense | $3M | $3M | $3M | $5M | $3M | $2M | $5M | $3M | $4M | $44M | $3M | $6M | |
| SG&A Expense | $3M | $3M | $4M | $4M | $4M | $3M | $5M | $4M | $7M | $7M | $6M | $7M | |
| Operating Expenses | $6M | $7M | $7M | $8M | $7M | $14M | $13M | $7M | · | · | · | $13M | |
| Operating Income | $-3M | $-4M | $-5M | $-7M | $-6M | $-14M | $-13M | $-7M | $-4M | $-47M | $-10M | $-13M | |
| Interest Expense | · | · | · | · | · | · | · | · | $1.8K | $729.6K | $267.0K | $4.7K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $19.0K | |
| Other Non-op | $5.7K | $-5.7K | $25.4K | $-1.6K | $1.1K | $-492 | $3.3K | $-24.6K | $-24.6K | $-85.4K | $-235.4K | $-326.9K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-14M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $-3M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-4M | $-7M | $-6M | $-11M | $-13M | $-7M | $-4M | $-54M | $-13M | $-14M | |
| EPS (Basic) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | · | · | · | · | · | · | · | |
| Shares (Basic) | 1,701,571 | 1,541,339 | 1,528,210 | 1,422,443 | 10,279,408 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 1,701,571 | 1,541,339 | 1,528,210 | 1,422,443 | 10,279,408 | · | · | · | · | · | · | · |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $6M | $9M | $13M | $18M | $12M | $10M | $571.6K | $6M | $4M | $132.2K | $3M | |
| Receivables | · | · | · | · | · | · | · | · | $0 | $3M | $0 | · | |
| Prepaid Expense | $166.3K | $422.0K | $603.8K | $556.1K | $479.4K | $842.0K | $722.1K | $555.9K | $285.0K | $1M | $247.3K | $204.0K | |
| Current Assets | $8M | $7M | $10M | $14M | $19M | $12M | $11M | $1M | $6M | $8M | $4M | $3M | |
| PP&E (Net) | · | · | · | $0 | $0 | $0 | $757 | $5.0K | $27.8K | $42.4K | $62.0K | $119.4K | |
| PP&E (Gross) | · | · | · | $0 | $50.2K | $57.0K | $57.0K | $89.4K | $358.3K | $349.1K | $332.3K | $586.1K | |
| Accum. Depreciation | · | · | · | $0 | $50.2K | $57.0K | $56.3K | $84.4K | $330.5K | $306.7K | $270.2K | $466.7K | |
| Goodwill | · | · | · | · | · | $0 | $9M | $3M | $3M | $3M | $3M | $3M | |
| Other Non-current Assets | $313.9K | $313.9K | $1M | $1M | $1M | $810.0K | $1M | $705.7K | $724.7K | $66.3K | $129.3K | $199.3K | |
| Total Assets | $8M | $7M | $11M | $15M | $20M | $13M | $22M | $14M | $19M | $21M | $17M | $16M | |
| Accounts Payable | $258.1K | $283.6K | $240.8K | $287.4K | $362.5K | $327.4K | $931.1K | $934.1K | $786.8K | $1M | $2M | $852.8K | |
| Accrued Liabilities | $709.9K | $610.6K | $568.8K | $785.8K | $1M | $574.0K | $464.0K | $664.0K | $1M | $838.9K | $1M | $1M | |
| Current Liabilities | $968.0K | $894.3K | $809.6K | $1M | $1M | $936.9K | $1M | $2M | $2M | $2M | $7M | $3M | |
| Capital Leases | · | · | · | · | · | $27.0K | $0 | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | $27.0K | $3M | $3M | $3M | $3M | $3M | $3M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $0 | $0 | $19.9K | $38.8K | $56.4K | |
| Total Liabilities | $968.0K | $894.3K | $809.6K | $1M | $1M | $964.0K | $4M | $5M | $5M | $5M | $10M | $6M | |
| Common Stock | $2.3K | $1.5K | $1.5K | $1.5K | $13.5K | $8.8K | $6.1K | $811 | $9.0K | $8.7K | $4.9K | $150.0K | |
| Paid-in Capital | $212M | $208M | $208M | $208M | $206M | $194M | $188M | $168M | $165M | $164M | $100M | $91M | |
| Retained Earnings | $-200M | $-197M | $-193M | $-189M | $-183M | $-177M | $-166M | $-153M | $-146M | $-142M | $-88M | $-76M | |
| Treasury Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| AOCI | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $575.7K | |
| Stockholders' Equity | $7M | $6M | $10M | $14M | $18M | $12M | $17M | $10M | $14M | $16M | $7M | $10M | |
| Liabilities + Equity | $8M | $7M | $11M | $15M | $20M | $13M | $22M | $14M | $19M | $21M | $17M | $16M | |
| Shares Outstanding | 2,291,056 | 1,542,139 | 1,540,684 | 1,516,659 | 13,439,612 | 8,745,207 | 6,065,441 | 783,865 | 8,717,541 | 4,585,800 | 4,585,800 | 139,297,282 |
现金流 8
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | $0 | $0 | $1.0K | · | · | · | · | $56.1K | $88.7K | |
| Stock-based Comp | $64.8K | $171.8K | $283.1K | $511.5K | $410.4K | $468.9K | $806.1K | $1M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-2M | $-3M | $-4M | $-5M | $-5M | $-4M | $-6M | $-6M | $1M | $-9M | $-5M | $-13M | |
| CapEx | · | · | · | · | · | · | · | $0 | $9.3K | $16.8K | $1.7K | $57.7K | |
| Investing Cash Flow | · | · | $0 | $-500.0K | $0 | $0 | $2.0K | $22.5K | $-9.3K | $-16.8K | · | · | |
| Stock Issued | $4M | $0 | · | $0 | $11M | $5M | $0 | · | · | · | $0 | $10M | |
| Financing Cash Flow | $4M | $0 | · | $0 | $11M | $5M | $16M | $1M | $0 | $13M | · | · | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | $0 |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 19.0% | -1.6% | 48.8% | 47.1% | 165.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 20.4% | 29.1% | 79.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 46.8% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3M | $3M | $3M | $2M | $1M | $436.9K | $17.1K | $0 | $8M | $3M | $0 | $0 | |
| Net Income TTM | $-3M | $-4M | $-4M | $-7M | $-6M | $-11M | $-13M | $-7M | $-4M | $-54M | $-13M | $-14M | |
| P/E | -1.4 | -1.6 | -1.3 | -0.6 | -23.5 | · | · | · | · | · | · | · | |
| P / Tangible Book | 0.7 | 1.0 | 0.5 | 3.2 | 9.4 | 14.6 | · | · | · | · | · | · | |
| Earnings Yield | -72.8% | -64.4% | -78.5% | -161.8% | -4.3% | · | · | · | · | · | · | · |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $660.6K | $806.9K | $766.3K | $1M | $589.9K | $593.3K | $648.8K | $614.2K | $726.4K | $510.8K | $672.0K | $611.2K | $651.0K | $605.8K | $487.0K | $414.2K | |
| R&D Expense | $552.0K | $661.4K | $773.4K | $756.5K | $656.6K | $879.0K | $1M | $368.0K | $933.8K | $944.3K | $975.6K | $1M | $903.2K | $595.3K | $1M | $398.8K | |
| SG&A Expense | $1M | $647.6K | $615.9K | $815.2K | $657.8K | $656.6K | $705.7K | $745.7K | $1M | $834.9K | $952.0K | $737.2K | $946.0K | $925.7K | $857.2K | $863.2K | |
| Operating Expenses | $2M | $1M | $1M | $2M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Operating Income | $-971.7K | $-502.1K | $-623.0K | $-544.7K | $-724.4K | $-942.4K | $-1M | $-499.5K | $-1M | $-1M | $-1M | $-1M | $-1M | $-915.2K | $-2M | $-847.8K | |
| Interest Income | $42.1K | $45.8K | · | · | $34.2K | $39.2K | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $-72 | $-21 | $159 | $4.0K | $1.5K | $78 | $-7.2K | $1.5K | $-21 | $52 | $404 | $-666 | $21.1K | $4.5K | $986 | $-1.7K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-929.7K | $-456.4K | $-579.1K | $-509.9K | $-688.7K | $-903.1K | $-1M | $-436.7K | $-1M | $-1M | $-1M | $-1M | $-1M | $-856.6K | $-1M | $-804.0K | |
| EPS (Basic) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 | $-0.83 | $-0.78 | $-0.77 | $-0.69 | $-0.69 | $-0.56 | $-2.03 | $-0.56 | |
| EPS (Diluted) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 | $-0.83 | $-0.78 | $-0.77 | $-0.69 | $-0.69 | $-0.56 | $-2.03 | $-0.56 | |
| Shares (Basic) | 2,294,364 | 2,291,056 | -2,924,846 | 1,542,139 | 1,542,139 | 1,542,139 | -3,081,866 | 1,541,722 | 1,540,799 | 1,540,684 | -3,045,766 | 1,532,600 | 1,524,717 | 1,516,659 | -14,855,930 | 1,431,659 | |
| Shares (Diluted) | 2,294,364 | 2,291,056 | -2,924,846 | 1,542,139 | 1,542,139 | 1,542,139 | -3,081,866 | 1,541,722 | 1,540,799 | 1,540,684 | -3,045,766 | 1,532,600 | 1,524,717 | 1,516,659 | -14,855,930 | 1,431,659 | |
| EBITDA | $-971.7K | $-502.1K | · | $-544.7K | $-724.4K | $-942.4K | · | $-499.5K | $-1M | $-1M | · | $-1M | $-1M | $-915.2K | · | $-847.8K |
资产负债表 18
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | $7M | · | · | · | $5M | · | $7M | $7M | $8M | $9M | $10M | $11M | $12M | $13M | $14M | |
| Prepaid Expense | $182.3K | $247.8K | $166.3K | $946.4K | $573.9K | $313.6K | $422.0K | $188.1K | $716.4K | $552.0K | $603.8K | $1M | $1M | $876.5K | $556.1K | $319.1K | |
| Current Assets | $7M | $8M | $8M | $5M | $5M | $5M | $7M | $7M | $8M | $8M | $10M | $11M | $12M | $13M | $14M | $14M | |
| Other Non-current Assets | $313.9K | $313.9K | $313.9K | $0 | $0 | $313.9K | $313.9K | $1M | $1M | $1M | $1M | $704.4K | $704.4K | $844.4K | $1M | $1M | |
| Total Assets | $7M | $8M | $8M | $5M | $5M | $6M | $7M | $8M | $9M | $9M | $11M | $12M | $13M | $14M | $15M | $16M | |
| Accounts Payable | $322.5K | $558.8K | $258.1K | $578.2K | $346.8K | $240.3K | $283.6K | $243.3K | $283.6K | $210.5K | $240.8K | $448.6K | $221.3K | $259.2K | $287.4K | $202.8K | |
| Accrued Liabilities | · | · | $709.9K | · | · | · | $610.6K | · | · | · | $568.8K | · | · | · | $785.8K | · | |
| Current Liabilities | $895.0K | $958.2K | $968.0K | $1M | $903.4K | $667.9K | $894.3K | $1M | $2M | $716.5K | $809.6K | $1M | $871.3K | $856.4K | $1M | $1M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Total Liabilities | $895.0K | $958.2K | $968.0K | $1M | $903.4K | $667.9K | $894.3K | $1M | $2M | $716.5K | $809.6K | $1M | $871.3K | $856.4K | $1M | $1M | |
| Common Stock | $2.3K | $2.3K | $2.3K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $15.2K | $1.5K | $14.3K | |
| Paid-in Capital | $212M | $212M | $212M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $207M | |
| Retained Earnings | $-201M | $-200M | $-200M | $-199M | $-199M | $-198M | $-197M | $-196M | $-196M | $-194M | $-193M | $-192M | $-191M | $-190M | $-189M | $-188M | |
| Treasury Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| AOCI | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | |
| Stockholders' Equity | $6M | $7M | $7M | $4M | $4M | $5M | $6M | $7M | $7M | $9M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Liabilities + Equity | $7M | $8M | $8M | $5M | $5M | $6M | $7M | $8M | $9M | $9M | $11M | $12M | $13M | $14M | $15M | $16M | |
| Shares Outstanding | 2,343,181 | 2,293,757 | 2,291,056 | 1,542,139 | 1,542,139 | 1,542,139 | 1,542,139 | 1,542,139 | 1,541,101 | 1,540,684 | 1,540,684 | 1,532,600 | 1,532,600 | 15,166,596 | 1,516,659 | 14,316,596 |
现金流 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $52.0K | $11.3K | $14.0K | $15.9K | $15.7K | $19.3K | $25.1K | $27.5K | $42.1K | $77.1K | $74.6K | $70.3K | $69.4K | $68.9K | $118.7K | $137.4K | |
| Operating Cash Flow | $-875.5K | $-536.4K | $-242.7K | $-658.2K | $-383.8K | $-1M | $-674.0K | $-459.0K | $-525.1K | $-1M | $-793.0K | $-949.6K | $-1M | $-1M | $-750.9K | $-1M | |
| Investing Cash Flow | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $0 |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -147.1% | -62.2% | · | -53.0% | -122.8% | -158.8% | · | -81.3% | -184.1% | -248.3% | · | -187.6% | -184.1% | -151.1% | · | -204.7% | |
| Net Margin | -140.7% | -56.6% | · | -49.7% | -116.8% | -152.2% | · | -71.1% | -175.4% | -234.0% | · | -172.7% | -161.4% | -141.4% | · | -194.1% | |
| EBITDA Margin | -147.1% | -62.2% | · | -53.0% | -122.8% | -158.8% | · | -81.3% | -184.1% | -248.3% | · | -187.6% | -184.1% | -151.1% | · | -204.7% | |
| ROA | -15.1% | -6.7% | · | -7.8% | -9.6% | -11.9% | · | -4.4% | -11.7% | -10.3% | · | -7.7% | -7.2% | -5.4% | · | -4.4% | |
| ROE | -17.7% | -7.6% | · | -9.3% | -11.6% | -13.1% | · | -4.9% | -13.2% | -11.1% | · | -8.3% | -7.8% | -5.8% | · | -4.6% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.4 | 7.9 | · | 4.6 | 5.9 | 8.2 | · | 7.0 | 5.0 | 11.7 | · | 10.5 | 13.8 | 15.0 | · | 13.5 | |
| Quick Ratio | · | 7.7 | · | · | · | 7.7 | · | 6.8 | 4.6 | 10.9 | · | 9.1 | 12.3 | 14.0 | · | 13.2 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
估值 (TTM) 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3M | $3M | · | $3M | $3M | $2M | · | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Net Income TTM | $-3M | $-3M | · | $-3M | $-3M | $-4M | · | $-4M | $-5M | $-4M | · | $-4M | $-5M | $-6M | · | $-6M | |
| Market Cap | $7M | $6M | · | $5M | $6M | $4M | · | $7M | $6M | $6M | · | $8M | $5M | $62M | · | $77M | |
| P/E | -2.1 | -1.7 | · | -1.9 | -1.8 | -1.1 | · | -1.7 | -1.4 | -1.4 | · | -2.0 | -0.9 | -1.3 | · | -2.0 | |
| P/S | 2.2 | 2.0 | · | 1.7 | 2.4 | 1.6 | · | 2.7 | 2.5 | 2.4 | · | 3.3 | 2.4 | 33.7 | · | 49.0 | |
| P/B | 1.1 | 0.9 | · | 1.2 | 1.4 | 0.8 | · | 0.9 | 0.8 | 0.7 | · | 0.7 | 0.4 | 4.8 | · | 5.3 | |
| P / Tangible Book | 1.1 | 0.9 | · | 1.2 | 1.4 | 0.8 | · | 0.9 | 0.8 | 0.7 | · | 0.7 | 0.4 | 4.8 | · | 5.3 | |
| P / Cash Flow | · | -11.5 | · | · | · | -4.0 | · | · | · | -5.0 | · | · | · | -55.9 | · | · | |
| Earnings Yield | -47.8% | -58.6% | · | -52.5% | -54.9% | -95.0% | · | -59.7% | -73.5% | -72.2% | · | -51.0% | -113.1% | -77.3% | · | -50.5% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $3M | $3M | $3M | $2M | $1M |
| 净收入 | $-3M | $-4M | $-4M | $-7M | $-6M |
| 稀释后每股收益 (EPS) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 8 家申报者 · $422K 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 3 (+2 与上一季度对比) | 0 (-5 与上一季度对比) | 0 (-1 与上一季度对比) | 3 (+1 与上一季度对比) | -17K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $341750 | 117440 | 80.90% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $38388 | 13184 | 9.09% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $36902 | 12681 | 8.74% | 股份 |
| SBI Securities Co., Ltd. | $2910 | 1000 | 0.69% | 股份 |
| Tower Research Capital LLC (TRC) | $2025 | 696 | 0.48% | 股份 |
| MORGAN STANLEY | $437 | 150 | 0.10% | 股份 |
| JTC Employer Solutions Trustee Ltd | $8 | 2700 | 0.00% | 股份 |
| Darwin Wealth Management, LLC | $5 | 2 | 0.00% | 股份 |
公司内部人士 1 位内幕人士 · 1 位高管 · 0 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| James F Parslow | Chief Financial Officer | 2017年4月3日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| CLS Therapeutics, LLC, CLS Therapeutics Ltd., Dmitry Genkin, Victor Tets, Georgy Tets, M. Scott Maguire ×3 申报 | 2024年3月18日 | — | 初始申报 | 被动投资 | SEC |
| PJSC Pharmsynthez, LLC SynBio, Dmitry Genkin | 2017年7月13日 | — | 初始申报 | — | SEC |
| Michael Scott Maguire | 2016年11月22日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 1 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |